Arbutin encapsulated micelles improved transdermal delivery and suppression of cellular melanin production

Ke Liang¹, Keming Xu¹, Dmitri Bessarab², Jonathan Obaje² and Chenjie Xu¹,3*

Abstract

Background: Hyperpigmentation is a skin disorder characterized by elevated production of melanin. Current treatment approaches mainly rely on the application of skin lightening chemicals, most of which have safety issues. Efficacy of delivery of the active ingredients to the target organ has also been a challenge. Transdermal based drug delivery platform has been shown to improve drug bioavailability, avoiding the hepatic first pass metabolism, decrease gastrointestinal side effects, and eventually enhance patient compliance.

Results: This article explores the utilization of micellar transdermal delivery technology to improve skin penetration and efficacy of arbutin, a hyperpigmentation agent. The suppression efficacy of cellular melanin production versus cell viability of four active ingredients commonly used in skin lightening products, namely allantoin, arbutin, glycolic acid, and hyaluronic acid were first compared. Arbutin was selected for the micellar delivery studies base on its comparatively low cytotoxicity and better performance in reducing melanin production. Micellar Arbutin cream was formulated using Urath® proprietary micellar technology and was assessed for its cellular melanin suppression efficacy and skin penetration capacity.

Conclusion: The results show that micellar arbutin cream improved both the delivery and cellular melanin suppression, suggesting that micellar transdermal delivery may have potential application in addressing hyperpigmentation skin disorders.

Keywords: Micellar transdermal drug delivery, Micelles, Hyperpigmentation, Melanin, Arbutin

Background

Melanin is an irregular light absorbing polymer produced by the melanocytes which are located in the basal layer of epidermis [1]. Melanin protects human skin and underlying tissues against ultraviolet (UV) rays and absorption of toxic chemicals [2]. However, excessive formation or accumulation of melanin in the skin causes hyperpigmentation skin disorders [3]. Melanin formation in skin cells can be reduced or blocked by some chemicals which are the common active ingredients in skin lightening products [4, 5]. Most of the chemicals decrease the production of melanin by suppressing tyrosinase, an enzyme governing melanin production. So that as existing skin cells are naturally exfoliated keratinocytes with less melanin come to the surface and provide a lighter skin [6, 7].

To reach the skin cells, however, the chemicals have to pass through the stratum corneum, which acts as highly resistant lipid barrier to penetration of foreign molecules into the skin [8]. Therefore in both the pharmaceutical and cosmetic fields, significant efforts have been put forth in attempts to overcome the barrier of the stratum corneum in order to deliver topically functional agents into the skin. For example, Kim disrupted the stratum corneum by using dissolving microneedle patch to deliver 4-n-butylresorcinol, a skin depigmentation agent [9]. Cell penetrating peptide conjugated liposomes were also used to enhance transdermal delivery of Polygonum aviculare L. extract [10]. Recently, lecithin organogel...
was described as a unique micellar system for the topical
delivery of drugs and bioactive agents including tacrolimus,
vitamins A and C, kojic acid, glycolic acid and other
molecules [11, 12]. To the best of our knowledge there is
no record of application of micelles for the transdermal
delivery of arbutin.

In this article, we compare the suppression efficiency
of cellular melanin production by four active ingredi-
ents commonly used in skin lightening products, namely
allantoin, arbutin, glycolic acid, and hyaluronic acid.
Due to comparatively lower cytotoxicity and higher
performance in reducing melanin production, arbutin
was selected from the four candidates for further stu-
dies. 5 % (w/w) arbutin was encapsulated in a micellar
matrix of the cream with the view to ascertain possible
effect of micellar formulation. Both the micellar and the
non-micellar arbutin (containing 5 % w/w arbutin) were
screened for their ability to suppress melanin production
in a B16-F10 mouse melanoma cell line. Furthermore,
we performed ex vivo skin penetration experiments in
a Franz cell using fresh porcine skin to demonstrate the
transdermal permeability of the micellar arbutin.

Methods
Glycolic acid (≥97 %) and allantoin (≥98 %) were pur-
chased from Fluka. Melanin, arbutin (≥98 %), hyalu-
oneic acid (≥98 %), and Penicillin–Streptomycin were
purchased from Sigma-Aldrich. phosphate buffer saline
(PBS) with pH 7.4 (1×), fetal bovine serum (FBS), and
Dulbecco minimum essential medium (DMEM) were
purchased from Gibco. Alamar blue was purchased from
Invitrogen. The porcine skin was obtained from the local
supermarket and doesn’t require any ethical approval
according to the national regulations. The care and use of
laboratory animals used in preliminary study were moni-
tored according to the approved protocols (BRC IACUC
#151001) of the Institutional Animal Care and Use Com-
mittee (IACUC) at the Biological Resource Center (BRC)
in Biopolis, Singapore.

Cell culture
B16-F10 mouse melanoma cell line (ATCC) was main-
tained in DMEM containing 10 % FBS and 1 % Penicil-
lin–Streptomycin (full medium) at 37 °C under 5 % CO2.

Suppression of cellular melanin production
Four different agents (arbutin, glycolic acid, hyaluronic
acid, and allantoin) were screened for their ability to
suppress the melanin production through cell experi-
ment. Briefly, B16-F10 cells were seeded at a density of
8000 cells per well in a 96 well plate 24 h before exper-
iments. The original culture medium in the wells was then
replaced with medium containing various concentrations
(0.1 mg/ml, 1 mg/mg, and 5 mg/ml) of the above four
agents. The concentrations were selected based on the
concentration ranges usually found in commercial prod-
ucts (allantoin recommended dosage is 0.5–2 %) [13,
14], arbutin (concentrations reported in the literature is
3–7 %) [15], glycolic acid (concentration reported in liter-
ature is 4–70 %) [16–18], and hyaluronic acid (concentra-
tion is up to 1 %) [19]). The serum concentration (10 %)
was controlled to be the same for all wells. The culture
was maintained for 5 days, during which each well was
imaged every day. On day five, the media from all wells
was transferred to a new plate and quantified for the
absorbance at 405 nm on UV–Visible spectrophotom-
eter (Shimadzu, UV-2450). The concentration of melanin
at each well was estimated by correlating the measured
absorbance with the standard curve between the melanin
concentration and absorbance.

Cell viability assay
Alamar blue assay was carried to analyze the cell viability
after the incubation with various concentrations of arbu-
tin, glycolic acid, hyaluronic acid, and allantoin. Briefly,
8000 cells were seeded per well in a 96 well plate 24 h
before the experiment. Then various concentrations
of arbutin, glycolic acid, hyaluronic acid, and allantoin
(0.1 mg/ml, 1 mg/mg, and 5 mg/ml) were added to the
wells for 24 h. Later, 10 μl of Alamar blue was directly
added to the wells for 2 h. The absorbance at 600 nm
was measured (Spectramax M5 Microplate/Cuvette Reader System, Molecular Devices). A series of cell dilu-
tions were prepared to derive a standard curve between
absorption and cell concentration.

Micellar arbutin
Typically, when the cream containing functional ingre-
dients is applied on the skin, the emulsion stability may
be affected by the changes in the relative concentration
of the continuous phase (solvent) on the skin environ-
ment. This presents a formulation challenge for effective
transdermal products. Both the emulsion stability and
the efficacy of absorption of the active ingredients may
be affected by the changes in the continuous phase. The
Urah® micellar system used here incorporates reverse
micellar transformation capability to address the change
in the concentration of the continuous phase on the skin,
thus enabling the micelle to work both as a solubilizer
and delivery vehicle on the skin [20]. The production of
arbutin-encapsulated micelles or micellar arbutin cream,
didn’t require any ethical approval
According to the national regulations. The care and use of
laboratory animals used in preliminary study were moni-
tored according to the approved protocols (BRC IACUC
#151001) of the Institutional Animal Care and Use Com-
mittee (IACUC) at the Biological Resource Center (BRC)
in Biopolis, Singapore.
5 % arbutin without encapsulated micelles) was formulated using the standard oil-in-water emulsification approach [21].

**Suppression of cellular melanin production with micellar arbutin cream**

This experiment was performed using the 24-well plate for transwell migration assay (8 μm pore, Cell Biolabs Inc.). 24 h before experiment, B16-F10 cells were seeded to the bottom chamber at a density of 8 × 10⁴ cells/well in 0.5 ml full medium. Then 100 mg of micellar arbutin cream, 100 mg of non-micellar arbutin cream (see the section above), or 5 mg of free arbutin powder was added onto the upper well. The plate was incubated at 37 °C with 5 % CO₂ for 5 days. Every day, the cells were imaged. 5 days later, the upper wells were removed and the absorbance of the media at the bottom chamber at 405 nm was measured with Spectramax M5 Microplate/Cuvette Reader System (Molecular Devices). The blank cream containing no arbutin was used as a control.

**Ex vivo skin penetration study with Franz cell**

Fresh porcine skin (abdominal skin) was used in the ex vivo skin permeation studies. The hair and subcutaneous fat were carefully removed before experiment. The porcine skin was placed and clamped between the donor and receptor compartments of a Franz cell assembly with the stratum corneum of the skin piece facing the donor compartment. The receiving compartment was filled with PBS, avoiding the air bubbles between the underside of the skin and the PBS solution. 1 g of micellar arbutin cream, 1 g of non-micellar arbutin cream or the blank cream (no arbutin) was applied homogeneously onto the stratum corneum of the skin. A magnetic stirrer was put into the bottom of Franz cell, which stirred continuously at 400 rpm. The PBS solution was sampled (100 µl) at 1, 2, 4, 8, 12 and 24 h respectively. Same volume of PBS was refilled back to the Franz cell each time after sampling.

The transmigrated arbutin was quantified by high performance liquid chromatography (HPLC) (Agilent 1100 HPLC VWD) on a LC column (Poroshell, 120 EC-C18, 4.6 × 100 mm, 2.7 μm) and detected at 222 nm. The mobile phase was a mixture of water:methanol:0.1 M hydrochloric acid (89:10:1, v/v/v) with 0.5 ml/min flow rate. The area of the arbutin peak was measured and converted to the concentration based on the standard curve.

**Statistical analysis**

All statistics were performed with the Origin Pro 8.0 (OriginLab). The data were analyzed by one-way ANOVA. *P < 0.05, **P < 0.01 were considered to indicate a statistically significant difference.

**Results and discussion**

**Melanin suppression activity and cytotoxicity**

Allantoin, arbutin, glycolic acid, and hyaluronic acid were firstly compared for their suppression of melanin production in B16-F10 mouse melanoma cells. The cells were incubated with these chemicals under four concentrations (0, 0.1, 1 and 5 mg/ml) for 5 days. At day 5, the cell medium was transferred to a new plate and the secreted melanin concentrations for each well were quantified by measuring the absorption at 405 nm and correlating the results to the concentration-UV absorption standard curve (Additional file 1: Figure S1). The viability of cells left in the original plate were analysed using alamar blue assay.

Based on the quantification of secreted melanin (Fig. 1a), glycolic acid had the strongest effect in inhibiting the melanin production at the 1 and 5 mg/ml concentrations whereas allantoin was the least effective at both 1 and 5 mg/ml. However, the cell quantification (Fig. 1b) revealed that both glycolic acid and hyaluronic acid were cytotoxic. The remaining numbers of cells in the wells after treatment with 1 and 5 mg/ml glycolic acid represented only 20–30 % of numbers of cells detected in the control wells. The daily imaging suggested that the lower melanin amounts observed for glycolic and hyaluronic acids were due to the decrease of cell viability (Additional file 1: Figure S2). In comparison, both allantoin and arbutin did not show any influence over the cell viability and proliferation at the three concentrations used.

Given the higher cell viability and relatively effective inhibition of cellular melanin production, arbutin was chosen for further micellar formulation studies.

**Micellar arbutin is a formulation with active arbutin**

The cream with micelle encapsulated arbutin (or micellar arbutin cream) with 5 % arbutin (w/w) was prepared as described in the experimental section. This was compared with the non-micellar arbutin cream. Through dynamic light scattering study (Additional file 1: Figure S3), the micellar arbutin was around 90 nm, which was close to the size of blank micelle (70 nm). If the arbutin was not encapsulated within the micelles, the particle size was around 250 nm.

To test whether the micellar arbutin retains its original melanin-suppression ability, we co-cultured the B16-F10 cells with non-micellar arbutin cream, free arbutin, micellar arbutin cream, and blank cream in a transwell (Fig. 2a). Transwell was used to prevent the physical contact between cream and cells. We expected that the melanin suppression efficiency of micellar arbutin cream would be somewhat lower in comparison to free arbutin, since the micelles with arbutin had to leave the cream...
phase before they got into the medium with cells. Based on the comparative melanin concentrations, addition of free arbutin reduced melanin concentration by 40% (relatively to the blank cream), micellar arbutin reduced melanin concentration by about 25%, whereas non-micellar arbutin by 10% (Fig. 2b). In addition, we did not see any significant cytotoxicity of micellar arbutin in the 5-days long experiment. Cells in the wells with free arbutin, micellar arbutin, non-micellar arbutin, and blank cream grew and proliferated at similar rates (Additional file 1: Figure S3). Thus, the micellar arbutin cream has strong advantage in the suppression of melanin production while retaining its safety credentials.

**Micellar arbutin cream shows enhanced transdermal activity**

We examined the skin penetration capacity of micellar arbutin in a static Franz diffusion cell (Fig. 3a). Fresh pig skin after the removal of fat and hair was used due to its similarity to human skin [22]. The transmigrated arbutin in the receiving well was quantified by HPLC (Additional file 1: Figure S4). The area of arbutin peak, identified with
standard samples was quantified and converted to the arbutin concentration by correlating with the standard curve (Additional file 1: Figure S5). As shown in Fig. 3b, there was a slight increase in the concentration of arbutin in the receiving well after 1 h for both micellar arbutin cream and non-micellar arbutin cream, in comparison to the blank cream. This suggests that same level of passive diffusion was taking place in both non-micellar arbutin at the initial stage. Four hours upon application, the micellar arbutin cream showed gradual increase in the concentration of arbutin delivered through the skin in comparison with non-micellar arbutin cream. The difference nearly doubled after 12 h. These data suggest that micellar arbutin cream can improve the steady delivery of arbutin through the skin over a long period of time.

**Conclusion**

Hyperpigmentation is the result of excessive melanin production by the pigment cells—melanocytes located in the basal layer of the epidermis. Existing treatment approaches use topically applied chemicals which activity either enhances the epidermal cell turn-over due to the peeling or exerts inhibitory action on the melanin synthesis machinery. The latter requires the penetration of skin barrier presented by *stratum corneum* and further diffusion of the active substance through other epidermal layers to target melanocytes in the basal layer. An efficient transdermal delivery system would increase the treatment efficacy and reduce the potential cytotoxicity of the active ingredient [5].

The aim of the present study is to evaluate the relative safety and inhibitory effect of four chemical compounds used in skin care and hyperpigmentation treatment products, and to further evaluate possible effects of micellar encapsulation on the most effective and least toxic candidate.

We compared the in vitro capacity of arbutin, glycolic acid, hyaluronic acid and allantoin to inhibit melanin synthesis while accessing their cytotoxicity (Fig. 1). It turns out that arbutin was most effective in suppressing the cellular melanin production while having the lowest cytotoxicity.

Previously, the micellar formulation has been used for transdermal delivery of glucosamine to treat osteoarthritis, and improved Ritchie Articular Index pain score from the baseline (day 0) in all demographic group and further enhanced functional abilities were evidenced [23]. Our preliminary data indicate that the glucosamine concentration in the mouse blood 2 h after the application of micellar glucosamine cream was about 10 times higher than that observed for oral delivery (Additional file 1: Figure S7). Here, arbutin was formulated with this technology and the activity of arbutin was retained in the formulation, about 80 % as effective as free arbutin (Fig. 2).

Finally, the ex vivo skin penetration experiment demonstrated that the micellar arbutin cream possesses enhanced transdermal functionality (Fig. 3). During the first 4 h of the experiment the levels of arbutin penetrated through the skin were similar for the micellar arbutin cream and non-micellar arbutin cream. However, the level rose dramatically thereafter for micellar arbutin compared to the non-micellar arbutin cream.
Taken together our data provide evidence that micellar arbutin formulation could improve arbutin delivery and thus enhance the suppression of melanin synthesis. Micellar arbutin therefore has the potential to be developed into transdermal delivery system to address hyperpigmentation skin disorders.

**Additional file**

**Additional file 1.** Figure S1. Concentration-UV absorption relationship of melanin. Figure S2. Daily imaging of B16-F10 mouse melanoma cells during a 5-day culturing with allantoin, arbutin, glycolic acid, or hyaluronic acid at various concentrations: Figure S3. Photos of diluted PBS solution of micellar arbutin cream (MA), blank cream (BM), and non-micellar arbutin cream (NMA) and their Hydrodynamic diameters. Figure S4. Daily imaging of B16-F10 mouse melanoma cells during a 5-day culturing with blank cream, free arbutin, micellar arbutin cream, and non-micellar arbutin cream. Figure S5. HPLC analysis of arbutin in the receiving well during the skin penetration experiment at different hours: Figure S6. Relationship between the arbutin concentrations and peak area in the HPLC measurement. Figure S7. Concentration of glucosamine in blood plasma upon oral administration of glucosamine solution and topical application of URAH micellar glucosamine cream.

**Abbreviations**

UV: ultraviolet; PBS: phosphate buffer saline; FBS: fetal bovine serum; DMEM: Dulbecco’s modified essential medium; HPLC: high-performance liquid chromatography.

**Authors’ contributions**

JO and CX conceived and designed experiments. KL performed experiments. JO, CX, DB and CX analysed and interpreted data. KK and CX wrote the manuscript. All authors read and approved the final manuscript.

**Author details**

1. School of Chemical & Biomedical Engineering, Nanyang Technological University, 70 Nanyang Drive, Singapore 637457, Singapore. 2. Urah® Transdermal Pte Ltd, 51 Ubi Avenue 1, #05-13, Singapore 408933, Singapore. 3. NTU-Northwestern Institute for Nanomedicine, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798, Singapore.

**Acknowledgements**

KL appreciates the support from the biomedical engineering master program, School of Chemical and Biomedical Engineering, Nanyang Technological University.

**Availability of data and materials**

All the data supporting our findings are contained within the manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Ethics approval and consent to participate**

The care and use of laboratory animals used in preliminary study were monitored according to the approved protocols (BRC IACUC #151001) of the Institutional Animal Care and Use Committee (IACUC) at the Biological Resource Center (BRC) in Bopolis, Singapore.

**Funding**

This project was supported by the biomedical engineering master program, School of Chemical and Biomedical Engineering, Nanyang Technological University.

**References**

1. Melanin Riley P. Int J Biochem Cell Biol. 1997;29(11):1235–9.
2. Rozanowska M, Sarna T, Land EJ, Truscott TG. Free radical scavenging properties of melanin: interaction of eu- and pheo-melanin models with reducing and oxidising radicals. Free Radic Biol Med. 1999;26(5):518–25.
3. Costin GE, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB J. 2007;21(4):976–94.
4. Parvez S, Kang M, Chung HS, Cho C, Hong MC, Shin MK, et al. Survey and mechanism of skin depigmenting and lightening agents. Phytother Res. 2006;20(11):921–34.
5. Solano F, Briganti S, Ricardo M, Ghanem H. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res. 2006;19(6):550–71.
6. Smit N, Vicancova J, Pavel S. The hunt for natural skin whitening agents. Int J Mol Sci. 2009;10(12):5326–49.
7. Scott JA, Banga AK. Cosmetic devices based on active transdermal technologies. Ther Deliv. 2015;6(9):1089–99.
8. Kim S, Yang H, Kim M, Baek JH, Kim SJ, An SM, et al. 4-n-butylresorcinol dissolving microneedle patch for skin depigmentation: a randomized, double-blind, placebo-controlled trial. J Cosmet Dermatol. 2015;15(1):16–23.
9. Kwon SS, Kim SY, Kong BJ, Kim JI, Noh GY, Im NR, et al. Cell penetrating peptide conjugated liposomes as transdermal delivery system of Polygumum aviculare L. extract. Int J Pharm. 2015;483(1–2):26–37.
10. Lapteva M, Mondon K, Moller M, Gurny R, Kalia YN. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Mol Pharm. 2014;11(9):2989–3001.
11. Raut S, Bhadorya SS, Uplanchiwar V, Mishra V, Gahane A, Jain SK. Lecithin organogel: a unique micellar system for the delivery of bioactive agents in the skin treatment of ageing. Acta Pharm Sin B. 2012;2(1):8–15.
12. Becker LC, Bergfeld WF, Belisso CD, Marks JG, Shank RC, et al. Final report of the safety assessment of allantoin and its related complexes. Int J Toxicol. 2010;29(3 suppl):845–975.
13. Igle G, Essiet G, Uboh F, Edet E. Rapid method for the identification and quantification of allantoin in body creams and lotions for regulatory activities. Int J Curr Microbiol App Sci. 2014;3(7):552–7.
14. Jeon JS, Lee MJ, Yoon MH, Park J-A, Yi H, Cho H-J, et al. Determination of arbutin, niacinamide, and adenosine in functional cosmetic products by high-performance liquid chromatography. Anal Lett. 2014;47(10):1650–60.
15. Andersson FA. Final report on the safety assessment of glycolic acid, ammonium, calcium, potassium, and sodium glycolates, methyl, ethyl, propyl, and butyl glycolates, and lactic acid, ammonium, calcium, potassium, sodium, and tea-lactates, methyl, ethyl, isopropyl, and butyl lactates, and lauryl, myristyl, and cetyl lactates. Int J Toxicol. 1998;17(1 suppl):1–241.
16. Saikar R, Arora P, Garg KV. Cosmeceuticals for hyperpigmentation: what is available? J Cutan Aesthet Surg. 2013;6(1):4–11.
17. Cotellec C, Peris K, Onorati MT, Fargnoli MC, Chimenti S. The use of chemical peels in the treatment of different cutaneous hyperpigmentations. Dermatol Surg. 1999;25(6):450–4.
18. Becker LC, Bergfeld WF, Belisso CD, Marks JG, Shank RC, et al. Final report of the safety assessment of hyaluronic acid, potassium hyaluronate, and sodium hyaluronate. Int J Toxicol. 2009;28(4 suppl):5–67.
19. Obaje OJ. Trans-acidolysis process for the preparation of carbohydrate fatty-acid esters. 2005;U.S. Patent No. 6849616 B2.
20. Garrett ER. Stability of oil-in-water emulsions. J Pharm Sci. 1965;54(11):1557–70.
21. Hall EJ, Giaccia A editors. Radiobiology for the radiologist. Lippincott Williams & Wilkins; 2011.
22. Ng GH, Lee YM, Obaje J. A transdermal glucosamine formulation improves osteoarthritic symptoms in an open clinical survey. Int J Pharm Pharm Sci. 2011;3(3):80–3.